Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Anlotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 8467 Neoplasms 5867 Prostatic Neoplasms 3971 Colorectal Neoplasms 3538 Lung Neoplasms 3224 Carcinoma, Non-Small-Cell Lung 3170 Pancreatic Neoplasms 2214 Carcinoma, Hepatocellular 2141 Leukemia, Myeloid, Acute 1990 Multiple Myeloma 1905 Stomach Neoplasms 1880 Neoplasm Metastasis 1687 Head and Neck Neoplasms 1661 Ovarian Neoplasms 1594 Lymphoma 1562 Brain Neoplasms 1543 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1534 Rectal Neoplasms 1486 Melanoma 1481 Colonic Neoplasms 1440 Leukemia 1357 Recurrence 1311 Uterine Cervical Neoplasms 1297 Glioblastoma 1180 Esophageal Neoplasms 1169 Lymphoma, Non-Hodgkin 1074 Leukemia, Lymphocytic, Chronic, B-Cell 1001 Squamous Cell Carcinoma of Head and Neck 965 Urinary Bladder Neoplasms 956 Lymphoma, Follicular 945

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04803851 2023-06-22

Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

Peking Union Medical College Hospital

Phase 1/2 Unknown

Gastrointestinal

Anlotinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡